NASDAQ : IMCR
Immunocore Holdings plc — Key statistics
Healthcare · Biotechnology · United Kingdom
Last price 30.49 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.57B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.57B |
| Enterprise Value | 1.12B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 51.50M |
| Shares Change (YoY) | +1.14% |
| Shares Change (QoQ) | -3.70% |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 87.02% |
| Float | 45.83M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.65 |
| Forward PS | 3.27 |
| PB Ratio | 3.74 |
| P/TBV Ratio | 3.74 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2.61 |
| EV / EBITDA | 1,488.02 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.47 |
| Quick Ratio | 4.15 |
| Debt / Equity | 1.04 |
| Debt / EBITDA | 575.34 |
| Debt / FCF | n/a |
| Interest Coverage | -0.23 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -4.47% |
| Return on Assets (ROA) | -0.16% |
| Return on Invested Capital (ROIC) | -0.21% |
| Return on Capital Employed (ROCE) | -0.32% |
| Weighted Average Cost of Capital (WACC) | 7.32% |
| Revenue Per Employee | $822,090 |
| Profits Per Employee | -$34,492 |
| Employee Count | 524 |
| Asset Turnover | 0.39 |
| Inventory Turnover | 43.66 |
Taxes
| Measure | Value |
|---|
| Income Tax | 15.34M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -7.18% |
| 50-Day Moving Average | 32.37 |
| 200-Day Moving Average | 31.76 |
| Relative Strength Index (RSI) | 46.38 |
| Average Volume (20 Days) | 513,005 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.80M |
| Short Previous Month | 7.90M |
| Short % of Shares Out | 16.83% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 17.07 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 430.78M |
| Gross Profit | 141.59M |
| Operating Income | -2.85M |
| Pretax Income | -2.73M |
| Net Income | -18.07M |
| EBITDA | 756,000 |
| EBIT | -2.85M |
| Loss Per Share | -$0.36 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 880.21M |
| Total Debt | 434.96M |
| Net Cash | 445.25M |
| Net Cash Per Share | $8.65 |
| Equity (Book Value) | 419.80M |
| Book Value Per Share | 8.15 |
| Working Capital | 815.85M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -34.96M |
| Capital Expenditures | -6.20M |
| Depreciation & Amortization | 3.61M |
| Net Borrowing | n/a |
| Free Cash Flow | -41.15M |
| FCF Per Share | -$0.80 |
Margins
| Measure | Value |
|---|
| Gross Margin | 32.87% |
| Operating Margin | -0.66% |
| Pretax Margin | -0.63% |
| Profit Margin | -4.20% |
| EBITDA Margin | 0.18% |
| EBIT Margin | -0.66% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.14% |
| Shareholder Yield | -1.14% |
| Earnings Yield | -1.17% |
| FCF Yield | -2.62% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $62.73 |
| Price Target Difference | 105.74% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 12.31% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.65 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |